Bivastat 250mg Injection

Bivastat 250 mg injection contains bivalirudin as its active component. It is an anticoagulant (blood thinner) used in cardiology, primarily in patients undergoing percutaneous coronary intervention (PCI) or angioplasty to reduce the risk of blood clot formation during the procedure. It serves as an alternative to heparin in patients at risk of or with a history of heparin-induced thrombocytopenia (HIT), a potentially serious complication of heparin therapy.

Bivalirudin is contraindicated in patients with known hypersensitivity or allergy to the drug or any of its components. As an anticoagulant, it increases the risk of bleeding and is contraindicated in patients with active, severe, or life-threatening bleeding, including gastrointestinal bleeding, intracranial bleeding, or bleeding disorders. It may not be suitable for patients with severely uncontrolled hypertension.

Patients with severe renal impairment or end-stage renal disease may require dosage adjustment or alternative anticoagulation strategies, as the drug can accumulate and increase bleeding risk. It is not appropriate for patients with known coagulation disorders or conditions predisposing them to bleed. Use is not recommended in patients with significant thrombocytopenia or a history of HIT unless no suitable alternatives exist.

Bivalirudin may not be appropriate for patients who have undergone recent major surgical procedures or experienced significant trauma due to increased bleeding risk. It is not recommended as the sole anticoagulant for patients with infective endocarditis or other conditions requiring extended anticoagulation duration. The medication may be used in elderly patients, but with caution. It is not typically used in paediatric populations.

Percutaneous coronary intervention (PCI) Heparin-induced thrombocytopenia (HIT) Anticoagulation during cardiac surgery

Bivastat 250 mg injection directly inhibits thrombin, a critical enzyme in the blood clotting process. Blocking thrombin prevents the conversion of fibrinogen into fibrin, effectively inhibiting blood clot formation. This mechanism is particularly useful in medical procedures like percutaneous coronary intervention (PCI) to maintain blood flow in coronary arteries while minimizing the risk of clot formation, thanks to its rapid onset and reversible effects.

Bivastat 250 mg injection is administered via the intravenous (IV) route. It is important to follow the dosing instructions provided on the product's packaging or as your healthcare provider recommends.

Bivastat 250 mg injection causes some side effects like all medications, although not everyone will experience them. Serious: Bleeding Allergic reactions Thrombosis Common: Bleeding Pain at injection site Headache

Bivastat 250 mg injection increases the risk of bleeding, so careful monitoring is crucial, especially in patients with kidney problems who may need dosage adjustments. While it has minimal impact on liver function, severe liver disease should still be monitored. Verify any allergies to heparin and take steps to prevent blood clot formation with appropriate dosing and monitoring. Be cautious of potential drug interactions, be prepared to manage allergic reactions, and use this medication during pregnancy or breastfeeding only when the benefits outweigh the risks. Limited data are available for pediatric use, and elderly patients may require extra monitoring. Additionally, be careful with alcohol consumption and avoid driving or operating heavy machinery if experiencing dizziness or other side effects.